Open Access
Open access
volume 10

Performance-based reimbursement for digital therapeutics in Germany: A misconceptualized opportunity

Publication typeJournal Article
Publication date2024-01-01
scimago Q2
wos Q1
SJR0.874
CiteScore3.5
Impact factor3.3
ISSN20552076
Abstract
Background

Germany has one of the oldest social security systems in the world. Population coverage has subsequently increased, reaching coverage of approximately 90% of the population in the statutory health insurance (SHI) system today. Before this background, Germany has been pioneering the integration of digital therapeutics (DTx) into its SHI system by the introduction of the Digital Healthcare Law (Digitale-Versorgung-Gesetz, DVG) in 2019. Thereby, patients became eligible for digital health applications (Digitale Gesundheitsanwendungen, DiGA), which are available upon prescription by qualified healthcare professionals.

Challenge

As conventional healthcare delivery often lacks direct outcome measures as and is mostly still reimbursed on a fee-for-service basis, DiGA offer the opportunity to continuously provide individual outcome and performance data. They are, therefore, well-suited for a performance-based payment framework. While the DVG introduced the option for performance-based reimbursement components in 2019 already, the ongoing debate about the value of DiGA and to what extent they can contribute to the healthcare system has now been reflected in a 2023 health policy bill by the German Federal Ministry of Health, which aims to introduce a mandatory performance-based reimbursement component for DiGA.

Proposal

In this light, we propose a framework for performance-based reimbursement of DiGA, involving an intervention-specific, performance-linked reimbursement framework with shared accountability between manufacturers and payers. The approach aims to align the often contradicting interests of the involved stakeholders to incentivize the delivery of high-value digital health care. Yet, the proposal also acknowledges the need for further research to establish a robust foundation for implementing such a framework.

Found 
Found 

Top-30

Journals

1
Rheumatology and Therapy
1 publication, 50%
Developing World Bioethics
1 publication, 50%
1

Publishers

1
Springer Nature
1 publication, 50%
Wiley
1 publication, 50%
1
  • We do not take into account publications without a DOI.
  • Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
2
Share
Cite this
GOST |
Cite this
GOST Copy
Benning L. et al. Performance-based reimbursement for digital therapeutics in Germany: A misconceptualized opportunity // Digital Health. 2024. Vol. 10.
GOST all authors (up to 50) Copy
Benning L., Teepe G. W., Pooth J. S., Hans F. P. Performance-based reimbursement for digital therapeutics in Germany: A misconceptualized opportunity // Digital Health. 2024. Vol. 10.
RIS |
Cite this
RIS Copy
TY - JOUR
DO - 10.1177/20552076241281199
UR - https://journals.sagepub.com/doi/10.1177/20552076241281199
TI - Performance-based reimbursement for digital therapeutics in Germany: A misconceptualized opportunity
T2 - Digital Health
AU - Benning, Leo
AU - Teepe, Gisbert Wilhelm
AU - Pooth, Jan Steffen
AU - Hans, Felix Patricius
PY - 2024
DA - 2024/01/01
PB - SAGE
VL - 10
PMID - 39347508
SN - 2055-2076
ER -
BibTex
Cite this
BibTex (up to 50 authors) Copy
@article{2024_Benning,
author = {Leo Benning and Gisbert Wilhelm Teepe and Jan Steffen Pooth and Felix Patricius Hans},
title = {Performance-based reimbursement for digital therapeutics in Germany: A misconceptualized opportunity},
journal = {Digital Health},
year = {2024},
volume = {10},
publisher = {SAGE},
month = {jan},
url = {https://journals.sagepub.com/doi/10.1177/20552076241281199},
doi = {10.1177/20552076241281199}
}